ClinicalTrials.gg
CompletedNCT02034747COSMOSUpdated Nov 1, 2024

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients

A Phase 4 interventional study of Advagraf and Corticosteroid in Kidney Transplant, sponsored by Astellas Pharma Korea, Inc.. Completed at 9 sites in South Korea. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

This study is a multicenter, randomized, comparison, open-label, phase IV study in kidney transplant recipients whose immunosuppressive regimen is converted from Cyclosporine with corticosteroid to Advagraf® with corticosteroid. The eligible patients will be randomized into either Arm 1 or Arm 2. The Arm 1 will be reduced corticosteroid slowly until 50% lower dose from 4 weeks to 12 weeks in the Advagraf®-based immunosuppressive regimen, and the Arm 2 will receive the same corticosteroid dose for 24 weeks with Advagraf ®.

Read the detailed description

The primary objective is to assess the changes in the GFR after 24 weeks of treatment between the group that was reduced corticosteroid slowly until 50% lower dose from 4 weeks to 12 weeks and the group with maintained corticosteroid in stable kidney transplant subjects whose regimen was converted from a CyA-based immunosuppressive regimen with corticosteroid to an Advagraf®-based immunosuppressive regimen with corticosteroid for kidney transplant subjects whose regimen was converted from a CyA-based immunosuppressive regimen.

The secondary objective is to assess the creatinine clearance rate, acute rejection, satisfaction of medication and safety of the group with a 50% reduced dose of corticosteroid and the group in which the Advagraf ®-based immunosuppressive regimen with maintained corticosteroid.

02

Conditions studied

  • Kidney Transplant

Keywords

  • Immunosuppressive regimen
  • Advagraf
  • kidney transplant
  • Corticosteroid
03

In context

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Had a kidney transplant at least 12 months before his/her enrollment in this study (including a kidney retransplantation).
  • Underwent a CyA-based regimen since his/her last transplantation. The CyA dose remained unchanged during the last four weeks before the subject's enrollment.
  • The immunosuppressive regimen (combination of medications) remained unchanged for a minimum of four weeks before the subject's enrollment.
  • ≥30 mL/min

Exclusion criteria

Exclusion Criteria:

  • Had received an organ transplant other than a kidney
  • Had an acute rejection episode within 12 weeks before his/her enrollment in this study, or had an acute rejection episode within 24 weeks before his/her enrollment in this study that required anti-lymphocyte antibody therapy
  • Had been diagnosed with new-onset after his/her transplantation, except for basocellular or squamous cell carcinoma of the skin that had been treated successfully
  • The subject received a kidney transplant from full-HLA identical donor
  • Known to have FSGS or MPGN Type II as an underlying disease
  • Has elevated /ALT and/or SGOT/AST and/or total levels ≥ 2 times the upper value of the normal range of the investigated site
  • Has liver cirrhosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Corticosteroid with the 50% reduced dose

    oral

    Drug: Advagraf · Drug: Corticosteroid

  • Active comparator
    Corticosteroid with the maintained dose

    oral

    Drug: Advagraf · Drug: Corticosteroid

Interventions

06

What researchers measure

Primary outcomes

  1. Change in the GFR before the treatment (baseline) to that on Week 24

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change in the GFR before the treatment (baseline) to that on Week 12

    Time frame: Baseline and Week 12

  2. Change in the creatinine clearance before the treatment (baseline) to those on Weeks 12 and 24

    Time frame: Baseline, Week 12 and Week 24

  3. Incidence of acute rejection

    Time frame: Up to Week 24

  4. Safety assessed by the incidence of adverse events, vital signs and Lab-test

    Time frame: Up to Week 24

  5. Physical examinations including cyclosporine related cosmetic side effect

    Time frame: Up to Week 24

07

Study locations

9 sites
  • Busan, South Korea
  • Chungcheongnam-do, South Korea
  • Daegu, South Korea
  • Gyeonggi-do, South Korea
  • Incheon, South Korea
  • Jeollabuk-do, South Korea
  • Jeollanam-do, South Korea
  • Seoul, South Korea
  • Ulsan, South Korea
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in Nov 2015, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Jan 13, 2014
StartActual
Nov 21, 2013
Primary completionActual
Nov 7, 2015
CompletionActual
Nov 7, 2015
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02034747
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Nov 21, 2013
Primary completion
Nov 7, 2015
Completion
Nov 7, 2015
Last update
Nov 1, 2024

Study contacts

Medical Director
principal investigator · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion